

**PB 86 of 2022**

**National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022   
(No. 9)**

*National Health Act 1953*

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 29 September 2022

**NIKOLAI TSYGANOV**

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Pharmaceutical benefits—early supply) Instrument 2015   
(PB 120 of 2015). 2

1 Name

1. This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 9)*.
2. This Instrument may also be cited as PB 86 of 2022.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 October 2022* | *1 October 2022* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)*

1. Schedule 1, omit entry for Alendronic acid with colecalciferol and calcium
2. Schedule 1, after entry for Dasatinib in the form Tablet 100 mg [*Maximum Quantity: 30; Number of Repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Decitabine with cedazuridine | Tablet containing decitabine 35 mg with cedazuridine 100 mg | 20 | 5 | 2 |  |
|  |  | 20 | 5 | 5 |  |

1. Schedule 1, entry for Enzalutamide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Enzalutamide | Capsule 40 mg | 20 | 112 | 2 |  |
|  |  | 20 | 112 | 5 |  |

1. Schedule 1, after entry for Ethosuximide in the form Capsule 250 mg

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Capsule 250 mg (s19A) | 20 | 200 | 2 |  |

1. Schedule 1, entry for Fremanezumab

*insert as first entry:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Solution for injection 225 mg in 1.5 mL single dose pre-filled pen | 20 | 1 | 2 |  |
|  |  | 20 | 1 | 5 |  |

1. Schedule 1, entry for Nifedipine

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Tablet 10 mg | 20 | 60 | 5 |  |
|  | Tablet 20 mg | 20 | 60 | 5 |  |

1. Schedule 1, after entry for Triamcinolone

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Trientine | Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine) | 20 | 200 | 5 |  |